TICKERNERD
Menu
PVLAPVLAHealthcare · Biotechnology

PVLA Stock Forecast: Palvella Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$142
−0.71% on the day

The 15 Wall Street analysts covering Palvella Therapeutics, Inc. hold a median 12-month price target of $232 — +63.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.0B
Ticker Nerd rank
31 / 100
Median analyst target
$232
Analysts covering
15
Total return, dividends reinvested
1W
−9.3%
1M
−1.6%
YTD
+35.3%
1Y
+175.9%
From 52W high
−10.3%
From 52W low
+182.4%
$50
$158
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PVLA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Palvella Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Value
77
Volatility
73
Quality
50
Accruals
44
Size
36
Revisions
28
Issuance
11
Growth
8

Momentum (92): The shares have been drifting up relative to others.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PVLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PVLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Oct 25Jan 26Apr 26Jul 26PVLAHigh $270Median $232Low $205

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $205Median $232High $270

The green dot is the last close — the median target sits +63.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 May 2026Chardan CapitalMaintainsBuy$240
21 May 2026Stephens & Co.ReiteratesOverweight$220
12 May 2026Stephens & Co.InitiatesOverweight—
31 Mar 2026Chardan CapitalMaintainsBuy—
24 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026Chardan CapitalMaintainsBuy—
25 Feb 2026BTIGMaintainsBuy—
25 Feb 2026MizuhoMaintainsOutperform—
24 Feb 2026Chardan CapitalMaintainsBuy—
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
29 Jan 2026BTIGReiteratesBuy—
16 Jan 2026BTIGReiteratesBuy—
7 Jan 2026MizuhoInitiatesOutperform—
16 Dec 2025Canaccord GenuityMaintainsBuy—
16 Dec 2025Chardan CapitalMaintainsBuy—
16 Dec 2025TD CowenMaintainsBuy—
16 Dec 2025Truist SecuritiesMaintainsBuy—
15 Dec 2025BTIGMaintainsBuy—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
5 Dec 2025BTIGInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PVLA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PVLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
7
Fundamentals

Palvella Therapeutics, Inc. (PVLA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.7×

Cheaper than 50% of US stocks

Price / sales
—
Price / book
9.4×

Cheaper than 11% of US stocks

EV / EBITDA
−51.5×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−46.6%

Higher than 22% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PVLA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PVLAPalvella Therapeutics, Inc.$2.0B
31
ZBIOZenas BioPharma, Inc.$2.0B
25
ZYMEZymeworks, Inc.$2.1B
72
GENBGenerate Biomedicines, Inc.$2.1B
1
BHVNBiohaven Ltd.$2.0B
24
STOKStoke Therapeutics, Inc.$2.0B
55
XNCRXencor, Inc.$2.0B
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Palvella Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PVLA news & analysis

Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel

Seeking Alpha · 19 Aug 2026positive

Palvella Therapeutics is advancing QTORIN rapamycin for microcystic lymphatic malformations, having posted positive Phase 3 SELVA data and begun a rolling NDA submission. The company plans to expand QTORIN across multiple mTOR-driven dermatological indications, supported by a recent $230M equity raise.

Why it matters — PVLA watchers would care because the first approval and a recent $230M equity raise could help Palvella build a repeatable multi-indication commercial platform while mitigating typical small-biotech funding risks.

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

MarketBeat · 16 Aug 2026positive

Palvella Therapeutics is advancing topical therapies for rare skin diseases and vascular malformations lacking FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations. The item notes a 2027 approval target as the rare-disease pipeline expands.

Why it matters — A PVLA watcher would care because the planned NDA submission for QTORIN rapamycin brings the company's lead candidate closer to a milestone in an area with no FDA-approved treatments.

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 5 Aug 2026neutral

Palvella Therapeutics announced that CEO Wes Kaupinen will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026.

Why it matters — The presentation at an investor conference provides Palvella with an opportunity to discuss its pipeline of therapies for rare skin diseases and vascular malformations with the investment community.

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Palvella Therapeutics, Inc. (PVLA). The item makes the company's latest quarterly earnings call discussion available to investors.

Why it matters — A PVLA watcher can review management's commentary on the company's second-quarter 2026 results directly from the earnings call.

Palvella Therapeutics Q2 Earnings Call Highlights

MarketBeat · 4 Aug 2026positive

Palvella Therapeutics stated it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations during the second half of 2026, with potential FDA approval targeted for the first half of 2027.

Why it matters — The reaffirmed submission and approval timeline gives PVLA watchers a clearer view of when the company's lead candidate could reach the market.

FAQ

Frequently asked questions about PVLA stock

What is the PVLA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Palvella Therapeutics, Inc. have a median 12-month price target of $232, with estimates ranging from $205 to $270. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PVLA stock a buy right now?

Of the 15 analysts covering Palvella Therapeutics, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palvella Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PVLA?

As at 22 Aug 2026, Palvella Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will PVLA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +63.9% from the last close, and Ticker Nerd's factor model ranks Palvella Therapeutics, Inc. 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PVLA stock forecast for 2030?

No analyst covering Palvella Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PVLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $205 to $270 over the next 12 months.

How has PVLA stock performed over the past year?

Palvella Therapeutics, Inc. returned +175.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Palvella Therapeutics, Inc. do?

Pavella Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders.

What is the latest news on PVLA?

The most recent item we track (Seeking Alpha, 19 Aug 2026): "Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel". Palvella Therapeutics is advancing QTORIN rapamycin for microcystic lymphatic malformations, having posted positive Phase 3 SELVA data and begun a rolling NDA submission. The company plans to expand QTORIN across multiple mTOR-driven dermatological indications, supported by a recent $230M equity raise.

Company

About Palvella Therapeutics, Inc.

Pavella Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders. The primary function of the company is to research and advance treatments that address unmet medical needs in the realm of genetic diseases, leveraging advanced biotechnological innovations. The company plays a significant role in the health care and pharmaceutical sectors, differentiating itself with its commitment to precision medicine approaches and personalized therapies. By concentrating on niche areas that are often overlooked by larger pharmaceutical firms, Pavella Therapeutics Inc. aims to provide hope and potential treatment options to patients with limited alternatives. In the financial markets, Pavella Therapeutics holds a distinctive position as a cutting-edge firm with the potential to drive significant impacts within its specialized domain. The company's activities contribute to the broader biotechnology landscape by enhancing understanding of genetic conditions and supporting the development of targeted biotherapeutic solutions.

CEO Mr. Wesley H. Kaupinen · 29 employees · United States · https://palvellatx.com